Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Janux Therapeutics, Inc.
januxrx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Eric Dobmeier was reclassified from a Class III director to a Class II director on April 28, 2026, as part of Janux Therapeutics' effort to balance board composition across its three director classes. This routine governance adjustment has minimal impact on company operations or investor interests.
Key Takeaways
Eric Dobmeier resigned as Class III director and was immediately reappointed as Class II director on the same date
The reclassification shortens Dobmeier's term expiration from 2027 Annual Meeting to 2026 Annual Meeting
2 more takeaways